Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04718740
Other study ID # FZPL-?-120
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 25, 2021
Est. completion date July 15, 2023

Study information

Verified date August 2023
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer. Secondary objective: To evaluate the safety of single dose of fluzoparib, caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion or fluzoparib in combination with caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date July 15, 2023
Est. primary completion date October 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subjects must meet all of the following criteria to enter the study: 1. Patients are willing to participate this research and sign informed consent forms (ICFs) 2. Patients must be = 18 years of age at the date of signing the informed consent; 3. Patients with histologically diagnosed relapsed high grade (or middle and low differentiation) serous ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by pathology; ovarian endometrioid adenocarcinoma = grade II; mixed type tumor: high grade serous type or endometrioid component = grade II should be more than 50%; 4. Patients with platinum sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer achieved complete or partial remission after platinum containing chemotherapy (carboplatin and cisplatin only). Platinum sensitive defined as having disease progression greater than 6 months after completion of their last dose of platinum chemotherapy. Patient must have received, at least 4 cycles of a platinum based chemotherapy regimen for the last chemotherapy course 5. ECOG Performance Status of 0-1 6. Patients must have a life expectancy of at least 3 months 7. Patients must have normal organ and bone marrow function measured prior to administration of study treatment as defined below: HB=100g/L; ANC=1.5×109/L; PLT=100×109/L or 1x UN TBIL=1.5×ULN; ALT?AST=3×ULN; Cr=1.5×ULN; Albumin>30g/L; 8. Agree to abstain from sex or use effective non-drug contraceptives from screening to at least 6 months after the last study drug administration (female subjects are also required to abstain or use effective non-drug contraceptives two weeks prior to study entry) Exclusion Criteria: Inclusion Criteria: Subjects must meet all of the following criteria to enter the study: 1. Patients are willing to participate this research and sign informed consent forms (ICFs) 2. Patients must be = 18 years of age at the date of signing the informed consent; 3. Patients with histologically diagnosed relapsed high grade (or middle and low differentiation) serous ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by pathology; ovarian endometrioid adenocarcinoma = grade II; mixed type tumor: high grade serous type or endometrioid component = grade II should be more than 50%; 4. Patients with platinum sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer achieved complete or partial remission after platinum containing chemotherapy (carboplatin and cisplatin only). Platinum sensitive defined as having disease progression greater than 6 months after completion of their last dose of platinum chemotherapy. Patient must have received, at least 4 cycles of a platinum based chemotherapy regimen for the last chemotherapy course 5. ECOG Performance Status of 0-1 6. Patients must have a life expectancy of at least 3 months 7. Patients must have normal organ and bone marrow function measured prior to administration of study treatment as defined below: HB=100g/L; ANC=1.5×109/L; PLT=100×109/L or 1x UN TBIL=1.5×ULN; ALT?AST=3×ULN; Cr=1.5×ULN; Albumin>30g/L; 8. Agree to abstain from sex or use effective non-drug contraceptives from screening to at least 6 months after the last study drug administration (female subjects are also required to abstain or use effective non-drug contraceptives two weeks prior to study entry) Exclusion Criteria: Subjects who do meet any of the following criteria will not be allowed to enter the study: 1. Patients with previously (within 5 years) or at the same time with other incurable malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in situ and breast cancer with no recurrence for more than 5 years after radical operation 2. 3 months prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor (PARPi) 3. Patients with central nervous system metastasis 4. Serous cavity effusion (including pleural effusion, ascites and pericardial effusion) with clinical symptoms and requiring symptomatic treatment; note: Patients with symptomatic serous cavity effusion can be included in the group if there is no disease, patients with symptomatic serous cavity effusion can be included in the group if they are treated with symptomatic treatment (anti-cancer drugs can not be used for serous cavity effusion treatment), and patients can be included in the group if judged by researchers 5. Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any gastrointestinal disorder or defect that would interfere with absorption of study drugs 6. There are clinical cardiac symptoms or diseases that can not be well controlled, such as: (1) NYHA grade 2 or above cardiac insufficiency, (2) unstable angina pectoris, (3) acute myocardial infarction within one year, (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention, (5) QTc > 470ms 7. Patients with abnormal coagulation function (INR > 1.5 or PT > ULN + 4 seconds), bleeding tendency or receiving thrombolytic or anticoagulant therapy 8. Contraindications of midazolam (allergic to benzodiazepine, myasthenia gravis, schizophrenia, severe depression patients) 9. Warfarin contraindications (liver and kidney dysfunction, severe hypertension, coagulation dysfunction with bleeding tendency, active ulcer, trauma, threatened abortion, recent surgery) 10. Patients with contraindications to repaglinide and bupropion (patients with type I diabetes, including insulin-dependent IDDM and C-peptide negative diabetes, diabetic ketoacidosis with or without coma, patients with anorexia nervosa or bulimia, patients with a history of severe epilepsy; patients with sudden abstinence or withdrawal of sedatives); patients with diabetes other than the above Abnormal control 11. Not recovered from the previous adverse events before the first medication (previous treatment adverse events, excluding hair loss and fatigue, recovered to = 1 level) 12. Other clinical trial drugs were taken within 4 weeks before the first medication; 13. CYP1A2, CYP3A4, CYP2C9, CYP2C19 inducers or CYP1A2, CYP3A4, CYP2C9 and CYP2C19 inhibitors or P-gp inhibitors were taken within 4 weeks before the first medication (for group A); CYP3A4, cyp2c8 and CYP2B6 inducers were taken within 4 weeks before the first medication or CYP3A4, cyp2c8 and CYP2B6 inhibitors or transporter OATP1B1 were taken within 2 weeks (or 5 half lives)/ P-gp inhibitor (for group B) 14. Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs within 14 days prior to day 1 15. Alcoholics within 3 months before the first medication (drinking 14 units of alcohol per week: 1 unit = 285 ml of beer, or 25 ml of spirits, or 100 ml of wine), and smokers within 3 months before the first medication (smoking = 5 cigarettes per day); 16. Ingestion of grapefruit or grapefruit products within 7 days before the first medication, or ingestion of food or drink containing caffeine, xanthine or alcohol within 72 hours before the first medication; strenuous exercise within 4 days before the first medication; or other factors affecting drug absorption, distribution, metabolism and excretion 17. Patients with history of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases, or organ transplantation 18. Syphilis infection or active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA = 500 IU / ml; hepatitis C reference: HCV antibody positive and HCV copy number > upper limit of normal value) 19. Patients with active infections requiring antimicrobial therapy (e.g. antibiotics, antiviral drugs, antifungal drugs); 20. According to the judgment of the researchers, there are concomitant diseases (serious diabetes, thyroid diseases, etc.) that seriously endanger the safety of patients or affect the completion of the study 21. Patients with history of drug allergy, or allergic to apatinib or ingredients 22. The researcher judges other situations that may affect the clinical research and the judgment of research results.

Study Design


Intervention

Drug:
fluzoparib
Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib

Locations

Country Name City State
China Hunan Cancer Hospital Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion Peak Plasma Concentration (Cmax) DAY1, DAY22
Primary Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion Area under the plasma concentration versus time curve (AUC) DAY1, DAY22
Secondary Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion Half life (t1/2) DAY1,DAY 22
Secondary Number of Participants With Treatment-Related Adverse Events Safety: Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination, vital signs, adverse events (NCI-CTC AE 5.0), etc. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT02195973 - Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Phase 1
Not yet recruiting NCT05270720 - Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer Phase 1
Not yet recruiting NCT06070285 - Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Completed NCT02303912 - Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT01802749 - Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Phase 3
Completed NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Phase 1
Recruiting NCT03564340 - Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Phase 1/Phase 2
Recruiting NCT05610735 - Combination Therapy for Recurrent Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02083536 - LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Phase 1
Completed NCT03430518 - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Phase 1
Recruiting NCT03618706 - Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer Phase 2
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT01851746 - A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer N/A
Active, not recruiting NCT06107868 - Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer Phase 1
Recruiting NCT06308406 - A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06365853 - A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Phase 2
Active, not recruiting NCT05335993 - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Phase 2
Completed NCT01381861 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Phase 2
Not yet recruiting NCT05126342 - Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Phase 2
Completed NCT02849353 - Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer Phase 1/Phase 2